{"name":"Cutia Therapeutics（Wuxi）Co.,Ltd","slug":"cutia-therapeutics-wuxi-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CU-40102 Spray","genericName":"CU-40102 Spray","slug":"cu-40102-spray","indication":"Dermatological condition (specific indication not publicly disclosed)","status":"phase_3"},{"name":"Lidocaine tetracaine cream","genericName":"Lidocaine tetracaine cream","slug":"lidocaine-tetracaine-cream","indication":"Topical anesthesia for dermatological procedures","status":"phase_3"}]}],"pipeline":[{"name":"CU-40102 Spray","genericName":"CU-40102 Spray","slug":"cu-40102-spray","phase":"phase_3","mechanism":"CU-40102 is a topical spray formulation designed to treat skin conditions, likely through local delivery of an active pharmaceutical ingredient to affected areas.","indications":["Dermatological condition (specific indication not publicly disclosed)"],"catalyst":""},{"name":"Lidocaine tetracaine cream","genericName":"Lidocaine tetracaine cream","slug":"lidocaine-tetracaine-cream","phase":"phase_3","mechanism":"Lidocaine and tetracaine are local anesthetics that block sodium channels in nerve cell membranes to inhibit pain signal transmission.","indications":["Topical anesthesia for dermatological procedures","Local pain relief for skin conditions"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPRWYzMkNnbWZxc3RFUkFTZHNQNTZDSDJ1ZWdoZ05RWk0wVVBMd0RyZHFGQmFZSkNJNzZmcHduQUFnUFB5ZWZlNS1zeWlxN1lROHprdzFlRko4TjBENWhBRnFmX0E1RmJ2bnpTUWVtSTVJR3pDRnphQm00WHBMRVo2R2JPLTFKYjlZS09sOFl2NzlzdTJl?oc=5","date":"2024-11-05","type":"pipeline","source":"Yahoo Finance","summary":"Global Alopecia Treatment Market is Anticipated to Surpass ~USD 4 Billion by 2030 | DelveInsight - Yahoo Finance","headline":"Global Alopecia Treatment Market is Anticipated to Surpass ~USD 4 Billion by 2030 | DelveInsight","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}